Docetaxel, Doxorubicin & Cyclophosphamide (TAC) for. Early Breast Cancer
|
|
- Paul Parks
- 7 years ago
- Views:
Transcription
1 Regimen: Docetaxel, Doxubicin & Cyclophosphamide (TAC) f Early Breast Cancer Indication Adjuvant chemotherapy f node-positive early breast cancer (NICE CG 80) Adjuvant chemotherapy f high risk node-negative breast cancer Regimen detail Day(s) Drug Dose Route 1 Doxubicin 50mg/m 2 IV 1 Cyclophosphamide 500mg/m 2 IV 1 Docetaxel (Taxotere ) 75mg/m 2 IV G-CSF: give one of the following agents (accding to local policy) Primary prophylaxis with GCSF is recommended 2-6 Filgrastim 60kg = 300μg od SC >60kg = 480μg od SC 2-6 Lenograstim 1.75m 2 = 263μg od SC >1.75 m 2 = 150μg/m 2 od 2 Pegfilgrastim (Neulasta ) 6mg stat SC At least 5 days of G-CSF (either filgrastim lenograstim) should be given, although me may be required in patients at high risk of neutropenia Pegfilgrastim (Neulasta ) should be given as a single dose on day 2 Administration Doxubicin and cyclophosphamide are given by slow intravenous bolus into the side-arm of a fast-flowing drip of 0.9% sodium chlide. Cyclophosphamide may also be given in ml 0.9% sodium chlide over 30 minutes Docetaxel is administered in a 250ml PVC-free sodium chlide 0.9% bag over 60 minutes. Doses >190mg should be diluted in 500ml (maximum concentration 0.74mg/ml). F the first cycle, docetaxel should be administered 1-hour after giving doxubicin and cyclophosphamide (AC). If well-tolerated, then docetaxel can be given immediately after the AC component f subsequent cycles. Frequency Patients should be observed closely f hypersensitivity reactions, particularly during the first and second infusions. If hypersensitivity reactions occur, min symptoms such as flushing localised cutaneous reactions do not require discontinuation of therapy. The infusion may be temparily interrupted and when symptoms improve re-started at a slower infusion rate. Severe reactions, such as hypotension, bronchospasm generalised rash/erythema require immediate discontinuation of docetaxel and appropriate therapy. Patients who have developed severe hypersensitivity reactions should not be re-challenged with docetaxel. Every 21 days Maximum 6 cycles Extravasation Doxubicin is a vesicant (Group 5) Docetaxel is an exfoliant (Group 4) Cyclophosphamide is a neutral agent (Group 1) Page 1 of 5
2 Premedication Emetogenicity Additional recommended supptive medication Pre- treatment evaluation Regular investigation Standard limits f administration to go ahead if blood results not within range, authisation to administer must be given by prescriber/consultant Dose modifications Haematological toxicity Renal impairment Dexamethasone 8mg bd PO f 3 days, starting the day befe each cycle of chemotherapy. Patient should receive 3 doses pri to treatment. In the case where 3 doses have not been taken, dexamethasone 20mg IV should be administered minutes pri to chemotherapy and the remaining 3 al doses should be administered as per standard. This regimen has moderate-high emetogenic potential - refer to local protocol Mouthwashes as per local policy H 2 antagonist Proton Pump Inhibit if required Ciprofloxacin 500mg bd from days 5-14 (i.e. f 10 days) should be considered as prophylactic treatment following an episode of febrile neutropenia FBC Baseline - results valid f 4 weeks LFT Baseline - results valid f 4 weeks U&E (inc. SrCr) Baseline - results valid f 4 weeks ECHO MUGA Baseline if significant cardiac histy previous anthracycline therapy, repeated if suspicion of cardiac toxicity as necessary FBC Pre D1 results valid f 72 hours, LFT Pre D1 results valid f 7 days U&E (inc. SrCr) Pre D1 results valid f 7 days Clinical Assessment Clinically assess patient pri to each cycle, particularly focusing on whether the patient has experienced infection, neurological, gastrointestinal, hypersensitivity, cutaneous oedematous symptoms. Consider risk of cardiotoxicity. Neutrophil count 1.0 x 10 9 /l Platelet count 100 x 10 9 /l Creatinine Clearance > 50ml/min Bilirubin < 1.5 x ALT +/- Alk Phos < 2.5 x Consider changing G-CSF treatment duration if neutrophil count >10x10 9 /L if the patient complains of intolerable bone pain Delay 1 week if neutrophils <1.0 x 10 9 /l and/ platelets <100 x 10 9 /l. Dose reduction should be considered if myelosuppression results in delay of subsequent courses despite GCSF. CrCl Cyclophosphamide Doxubicin dose (ml/min) dose Docetaxel dose >20 100% 100% 100% % 75% 100% <10 50% reduction reduction reduction of doxubicin and docetaxel in severe renal impairment (CrCl <10ml/min) discuss with consultant Page 2 of 5
3 Hepatic impairment Bilirub AST +/- ALT Alk Phos Doxubicin Cyclophosphamide Docetaxel x and 3-5 x >5 x >1.5 x >3.5x >2.5 x 5-10 x >10 x 50% 100%* 75% 25% 100%* Omit. Consider alternative regimen reduction / use alternative regimen Not recommended. Clinical decision Contra-indicated. Consider alternative regimen * Cyclophosphamide is not recommended in patients if bilirubin > 1.5 x AST/ALT >2 3x, but exposure to active metabolites may not be increased and therefe a dose reduction may not be necessary. Consultant decision. NCI Common Toxicity Criteria Toxicity Definition Dose adjustment Febrile neutropenia Stomatitis & Mucositis Other toxicities ANC <0.5 x 10 9 /l plus fever requiring IV antibiotics +/- hospitalisation f Grade III painful erythema ulcers requiring rehydration resolving to Grade I less by day 21 Grade III/IV toxicity (except alopecia) Consider a longer prophylactic course of conventional G-CSF f subsequent cycles and give a 20% reduction of doxubicin, cyclophosphamide and docetaxel. Also consider the prophylactic use of ciprofloxacin 500mg bd from days 5-14 (i.e. f 10 days). 20% reduction of doxubicin and docetaxel Continue with 20% dose reduction of suspected causative agent(s) provided toxicity has resolved to Grade I less If further toxicity occurs, an additional reduction may be made after discussion with consultant. Defer treatment f any grade III/IV non-haematological toxicity (excluding alopecia) If a delay of me than 3 weeks is required f recovery, me than 2 dose reductions are necessary, the patient should discontinue treatment Adverse effects the contents of the table indicate the adverse effects that should be included in consent to treatment fms Rare Serious Side Effects Grade 3/4 febrile neutropenia Myelosuppression Risk of second malignancy Cardiac toxicity Teratogenicity Long term risk of early menopause, reduced fertility Peripheral neuropathy Frequently occurring Side Effects Nausea and vomiting Fatigue Stomatitis and mucositis Taste disturbance Diarrhoea Alopecia Se veins (phlebitis) Other side effects include: loss of appetite, taste disturbance, myalgia, neuralgia, Page 3 of 5
4 fluid retention, skin sensitivity, nail changes, bladder irritation (i.e. haemrhagic cystitis), allergic reactions and altered liver and kidney function. Significant drug interactions F full details consult product literature/ reference texts Comments Enzyme inducers/inhibits - in vitro studies suggest that CYP3A inhibits (such as ketoconazole and erythromycin) will raise docetaxel levels, whereas CYP3A inducers (such as rifampicin and barbiturates) will reduce docetaxel levels. Cardiotoxicity has been associated with anthracyclines, with adverse events being me common in patients with a pri histy of conary artery disease. Caution must be taken in patients with a histy of significant cardiac disease, arrhythmias angina pectis. Cumulative Doses Life time cumulative dose doxubicin 450mg/m 2 References National Institute f Health and Clinical Excellence. Clinical Guideline 80 Early and locally advanced breast cancer. Diagnosis and treatment, February 2009 [internet]. Accessed 06/04/2011 available at Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, et al. Adjuvant Docetaxel f High-Risk, Node-Negative Breast Cancer. N Engl J Med 2010; 363: Perez E A, TAC - A New Standard in Adjuvant Therapy f Breast Cancer? N Engl J Med 2005; 352; 22: Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Ardrover E, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxubicin, cyclophosphamide (TAC) 5-fluouracil, doxubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocytecolony stimulating fact to the TAC regimen. Ann Oncol 2006; 17: Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J-P, Weaver C,et al. Adjuvant Docetaxel f Node-Positive Breast Cancer. N Engl J Med 2005; 352: Daniels S. Nth London Cancer Netwk, Dose adjustment f cytotoxics in hepatic impairment [internet]. accessed 16/04/2009 available at Daniels S. Nth London Cancer Netwk,. Dose adjustment f cytotoxics in renal impairment [internet]. accessed 16/04/2009 available at Baxter K, edit. Stockley s Drug Interactions. Pharmaceutical Press; Accessed on line on 06/05/09 available at Summary of Product Characteristics Doxubicin solution f injection (Pfizer) [internet]. accessed 01/09/2010 available from Summary of Product Characteristics Taxotere (Docetaxel) 20mg and 80mg concentrate and solvent f infusion (Sanofi Aventis) [internet]. accessed 21/05/2009 available from Summary of Product Characteristics TAXOTERE (Docetaxel) 20 mg/1ml and 80mg/4ml and 160 mg/8ml concentrate f solution f infusion (Sanofi Aventis) [internet]. Accessed 01/09/2010 available from Summary of Product Characteristics Cyclophosphamide 500mg injection (Baxter) [internet]. accessed 11/11/2009 available from Page 4 of 5
5 Allwood M, Stanley A, Wright P, edits. The cytotoxics handbook. 4 th ed. Radcliffe Medical Press Trissel LA. Handbook of Injectable Drugs. 15th ed. American Society f Health- Systems Pharmacists Accessed on line on 06/05/09 available at Document title TAC f Breast Cancer Document number Approval date 15/10/2010 Written by Jeremy Braybrooke, Consultant Medical Oncologist, BHOC, and Chair, ASWCS Drugs and Therapeutics Committee Checked by Becky Bagnall, Consultant Pharmacist, NBT Authised by Jeremy Braybrooke, Chair ASWCS Drugs and Therapeutics Committee Review date 15/10/2011 Document reviewed by Version number 1.2.a Summary of changes Version 1.2.a New indication added Page 5 of 5
Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer
Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer Indication Adjuvant treatment for node positive early breast cancer This protocol is subject to local
More informationDocetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer
Regimen: Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer Indication Approved for the treatment of early and locally advanced breast cancer in
More informationAC-Docetaxel: Doxorubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer
AC-Docetaxel: Doxubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer Indication: Neoadjuvant therapy f high risk and fit Breast Cancer patients, suitable f a taxane containing regimen AC Regimen
More informationDocetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer
Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient
More informationWest of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol
West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol FEC-DH in the adjuvant treatment of Breast Cancer (BRWOS- 031/1) Indication Adjuvant chemotherapy for HER2+ve Early Breast Cancer Eligibility
More informationBreast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer
Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Indication: Neoadjuvant or adjuvant therapy in node positive patients. Also considered in
More informationRegimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral)
Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral) Indication CLL 1st line as per NICE TAG 174 CLL (relapsed) as per NICE TAG 193 Regimen details Day Drug Dose Route Cycle 1 1 Rituximab 375mg/m
More informationBreast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment of breast cancer Regimen details: Doxorubicin 60mg/m 2 IV Day 1 Cyclophosphamide
More informationBreast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail
Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Indication: Neoadjuvant or adjuvant therapy for elderly and frail patients with breast
More informationRegimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda ))
Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda )) Indication Regimen details Administration First line palliative treatment for locally advanced, inoperable oesophago-gastric cancer for
More informationThis regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs
Regimen : Ipilimumab for Advanced Melanoma ICD10 code Codes pre-fixed with C43. Indication Regimen detail Ipilimumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma
More informationLung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)
Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed
More informationLung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma
More informationWest of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)
West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility
More informationRegimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen)
Regimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen) Indications This is NOT a NICE-approved treatment. Please ensure that this regimen is locally
More informationRegimen: Gemcitabine & Carboplatin for NSCLC
Regimen: Gemcitabine & Carboplatin for NSCLC ICD10 codes Codes pre-fixed with C34. Indications Regimen details First-line chemotherapy for advanced (stage IIIB/IV) non-small cell lung cancer (NICE CG121)
More information5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol)
5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol) Indication: Adjuvant Chemo-radiotherapy for patients with resectable adenocarcinoma of the stomach
More informationThames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer
Network Chemotherapy Protocols Breast Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.nhs.uk. Any correspondence about the protocols
More informationBCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)
BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) Protocol Code Tumour Group Contact Physician UGUTIP Genitourinary Dr.
More informationNORDIC. Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue)
NORDIC C) CODOX (R) CODOX M/ (R) IVAC Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue) ICD-10 code C83.13 Regimen details (R) maxi-chop
More informationRegimen : Cetuximab ICD10 Codes pre-fixed with C18, C19, C20
Regimen : Cetuximab ICD10 Codes pre-fixed with C18, C19, C20 Indications First-line metastatic, k-ras wild-type colorectal cancer in combination with standard chemotherapy (in patients otherwise ineligible
More informationBCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:
More informationCycle frequency: Every four weeks Total number of cycles: 6-8
Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and
More informationSchedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8
Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total
More informationCycle frequency: Every three weeks Total number of cycles: 3 or 4
BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs
More informationRegimen : Irinotecan+Modified de Gramont (FOLFIRI)
Regimen : Irinotecan+Modified de Gramont (FOLFIRI) Indication Treatment of first line or second line palliative therapy for stage IV or relapsed colorectal cancer. Regimen details Administration For performance
More informationFludarabine based chemotherapy [Fludarabine, FC, FCR, FMD]
Approved Haematology Chemotherapy Protocol Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD] MCCN Ref OPCS Proc OPCS Del CLFLUD X70.5 X72.3 IV CLFC X70.4 X72.2 IV X73.1 O CLFCR X71.5 X72.1 LYFMD
More informationNetwork Chemotherapy Regimens
Network Chemotherapy Regimens Lung Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.org.uk. Any correspondence about the protocols
More informationBCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )
BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen
More informationSchedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2
Doxorubicin/Cisplatin Osteosarcoma - neoadjuvant Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 (3 before surgery) Ensure adequate renal function Pre & post-hydration,
More informationRegimen : Bevacizumab for metastatic colorectal cancer ICD10 codes pre-fixed with: C18, C19, C20
Regimen : Bevacizumab for metastatic colorectal cancer ICD10 codes pre-fixed with: C18, C19, C20 Indications First or second line treatment of advanced colorectal cancer, in combination with irinotecan
More informationNCCP Chemotherapy Protocol. Afatinib Monotherapy
Afatinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
More informationPREMEDICATIONS: Agent(s) Dose Route Schedule
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationRegimen : Oxaliplatin+Modified de Gramont (FOLFOX)
Regimen : Oxaliplatin+Modified de Gramont (FOLFOX) Indication Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumour Treatment of first line or second line palliative
More informationThames Valley Chemotherapy Regimens
Chemotherapy Regimens Lung Cancer Notes from the editor These regimens are available on the Network website www.tvcn.org.uk. Any correspondence about the regimens should be addressed to: Sally Coutts,
More informationClair Clark, Cancer Care Pharmacist Beatson West of Scotland Cancer Centre
Clair Clark, Cancer Care Pharmacist Beatson West of Scotland Cancer Centre An audit of neutropenic complications in breast cancer patients receiving adjuvant or neo-adjuvant chemotherapy with FEC-D in
More informationCycle frequency: Every three weeks Total number of cycles: 6
Carboplatin/Paclitaxel Ovarian Cancer Adjuvant, Advanced Paclitaxel 175mg/m 2 500mls 5% dex/3hrs Day 1 Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Anti-emetic group - Moderately high Paclitaxel given first
More informationHospital Outpatient Coding and Billing Information Sheet for Neulasta and NEUPOGEN
Hospital Outpatient Coding and Billing Information Sheet for Neulasta and Neulasta Delivery Kit Neulasta Prefilled Syringe For assistance contact 1-844-MYNEULASTA (1-844-696-3852) or visit www.amgenassistonline.com
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationBreast Cancer. Breast Cancer Page 1
Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or
More information3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP
PRESCRIBING INFORMATION 3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP IV Fluid and Electrolyte Replenisher Baxter Corporation Mississauga, Ontario L5N 0C2 Canada Date of Revision:
More informationChemotherapy Order Assessment and Review
Chemotherapy Order Assessment and Review Contents Introduction... 2 Step 1: Verify Patient Information... 2 Step 2: Confirm Protocol Matches Clinical Indication and Eligibility for Treatment... 2 Step
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More information1 Acute Myeloid Leukaemia
1 Acute Myeloid Leukaemia 1.17 Idarubicin Pre-treatment Evaluation Morphology of blood and bone marrow aspirate. Trial patients: send 6 unstained slides to Leeds General Infirmary. Trephine biopsy and
More informationSOP for Screening of Adult Chemotherapy Electronic Prescriptions
SOP for Screening of Adult Chemotherapy Electronic Prescriptions Contents The following steps should be followed in screening a chemotherapy prescription on ARIA: 1. Patient details 2 2. Patient medical
More informationLEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationRegimen: Carboplatin + Paclitaxel
Regimen: Carboplatin + Paclitaxel Indications Regimen details Administration 1. Post surgical adjuvant or neoadjuvant (as in the EORTC 55791 trial) or relapse therapy for stage IC to IV ovarian, fallopian
More informationSpecial pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Eribulin SYNONYM(S): Eribulin mesylate COMMON TRADE NAME(S): HALAVEN CLASSIFICATION: antimicrotubule agent Special pediatric considerations are noted when applicable, otherwise adult provisions
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion. Paracetamol
PACKAGE LEAFLET: INFORMATION FOR THE USER PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion Paracetamol Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationThis 2-part article will discuss 9 anticancer. Commonly Used Chemotherapy Drugs Part 1. M e d i c a t i o n s. Clinician s Brief.
M e d i c a t i o n s O N C O L O G Y Peer Reviewed Antony Moore, BVSc, MVSc, Diplomate ACVIM (Oncology) Veterinary Oncology Consultants, Sydney, Australia Commonly Used Chemotherapy Drugs Part 1 This
More informationMANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol)
MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) 1. Hepatotoxicity: In Active TB Disease a. Background: 1. Among the 4 standard anti-tb drugs,
More informationA guide to the accelerated elimination procedure
A guide to the accelerated elimination procedure Prescribing information and information on adverse event reporting can be found on the last page. What is the accelerated elimination procedure? An accelerated
More informationDRUG NAME: Pertuzumab
DRUG NAME: Pertuzumab SYNONYM(S): COMMON TRADE NAME(S): PERJETA CLASSIFICATION: monoclonal antibody Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM
More informationLondon Cancer. Mesothelioma Lung Protocols
London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationDocetaxel (Taxotere) This booklet explains what docetaxel is, when it may be prescribed, how it works and what side effects may occur.
Docetaxel (Taxotere) This booklet explains what docetaxel is, when it may be prescribed, how it works and what side effects may occur. Treatment Lorem ipsum and dolore side effects estes 2 Call our Helpline
More informationFor the Patient: BRAJFECD Other Names: Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel
For the Patient: BRAJFECD Other Names: Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel BR = BReast AJ = AdJuvant F = Fluorouracil E = Epirubicin C =
More informationWhat s New With HER2?
What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston
More informationShared Care Guideline for the use of Leflunomide for Rheumatoid Arthritis
Shared Care Guideline for the use of Leflunomide for Rheumatoid Section 1: Agreement for transfer of prescribing to GP Please sign this form and return it to the named consultant if you are willing to
More informationChapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationBeaumont Hospital Department of Nephrology and Renal Nursing. Guideline for administering Ferinject
Beaumont Hospital Department of Nephrology and Renal Nursing Guideline Name: Guideline for administering Ferinject Guideline Number: 18 Guideline Version: a Developed By: Louise Kelly CNM 1 Renal Day Care
More informationCare Pathway for the Administration of Intravenous Iron Sucrose (Venofer )
Departments of Haematology, Nephrology and Pharmacy Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer ) [Care Pathway Review Date] Guidance for use This Care Pathway is intended
More informationFEC chemotherapy. The drugs that are used. How treatment is given
Macmillan and Cancerbackup have merged. Together we provide free, high quality information for all. FEC chemotherapy This fact sheet is about a chemotherapy treatment for breast cancer called FEC. It describes
More informationCyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft
INDICATIONS Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft Aplastic Anaemia (patients under 40 years) PRE-ASSESSMENT Ensure pre-transplant work-up form is complete Ensure patient has triple
More informationActive centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationVAD Chemotherapy Regimen for Multiple Myeloma Information for Patients
VAD Chemotherapy Regimen for Multiple Myeloma Information for Patients The Regimen contains: V = vincristine (Oncovin ) A = Adriamycin (doxorubicin) D = Decadron (dexamethasone) How Is This Regimen Given?
More informationTC Chemotherapy Regimen (Docetaxel + Cyclophosphamide)
TC Chemotherapy Regimen (Docetaxel + Cyclophosphamide) TC is a regimen or treatment plan that includes a combination of chemotherapy drugs that your doctor prescribed for the treatment of your cancer.
More informationInpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
More informationMy Treatment Diary. People shown are not actual patients.
My Treatment Diary Please see Important Safety Information on pages 4-9, and Patient Information and full Prescribing Information, including Boxed WARNING, in the back pocket. People shown are not actual
More informationChemotherapy for head and neck cancers
Chemotherapy for head and neck cancers This information is from the booklet Understanding head and neck cancers. You may find the full booklet helpful. We can send you a free copy see page 7. Contents
More informationHydration Protocol for Cisplatin Chemotherapy
Betsi Cadwaladr University Health Version: 1.3 CSPM2 Hydration Protocol for Cisplatin Chemotherapy Date to be reviewed: July 2018 No of pages: 9 Author(s): Tracy Parry-Jones Author(s) title: Lead Cancer
More informationTC: Docetaxel and Cyclophosphamide
PATIENT EDUCATION patienteducation.osumc.edu What is TC? It is the short name for the drugs used for this chemotherapy treatment. The two drugs you will receive during this treatment are Docetaxel (Taxotere
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationRivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationPatient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T. Patient s first names. Date of birth.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas
More informationTreating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
More informationBCCA Protocol Summary for Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and rituximab in Diffuse Large B-cell Lymphoma
BCCA Protocol Summary for Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and rituximab in Diffuse Large B-cell Lymphoma Protocol Code Tumour Group Contact Physician LYCHOPRMTX Lymphoma
More informationReference ID: 3793488
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ABRAXANE safely and effectively. See full prescribing information for ABRAXANE. ABRAXANE for Injectable
More informationGuidelines for the Use of Naloxone in Palliative Care in Adult Patients
Guidelines for the Use of Naloxone in Palliative Care in Adult Patients Date Approved by Network Governance May 2012 Date for Review May 2015 Changes between Version 1 and 2 1. Guideline background 2.
More informationGuideline for the use of subcutaneous hydration in palliative care (hypodermoclysis)
Guideline for the use of subcutaneous hydration in palliative care (hypodermoclysis) Date Approved by Network Governance September 2012 Date for Review September 2015 Page 1 of 7 1 Scope of Guideline 1.1
More informationREVLIMID and IMNOVID for Multiple Myeloma
REVLIMID and IMNOVID for Multiple Myeloma What is Multiple Myeloma? Multiple myeloma (MM) is a persistent and life-threatening blood cancer that is characterised by tumour proliferation and immune suppression.
More informationI will be having surgery and radiation treatment for breast cancer. Do I need drug treatment too?
What is node-positive breast cancer? Node-positive breast cancer means that cancer cells from the tumour in the breast have been found in the lymph nodes (sometimes called glands ) in the armpit area.
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationPRODUCT MONOGRAPH ALIMTA
PRODUCT MONOGRAPH Pr ALIMTA Pemetrexed Disodium for Injection 100 mg or 500 mg pemetrexed per vial Antineoplastic Agent Eli Lilly Canada Inc. 3650 Danforth Avenue Toronto, Ontario M1N 2E8 1-888-545-5972
More informationCVP Chemotherapy Regimen for Lymphoma Information for Patients
CVP Chemotherapy Regimen for Lymphoma Information for Patients The Regimen Contains: C: Cyclophosphamide (Cytoxan ) V: Vincristine (Oncovin ) P: Prednisone How Is This Regimen Given? CVP is given every
More informationEastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families
Eastern Health MS Service Tysabri Therapy Information for People with MS and their Families The Eastern Health MS Service has developed this information for you as a guide through what will happen to you
More information**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
More informationPERIPHERAL STEM CELL TRANSPLANT INTRODUCTION
PERIPHERAL STEM CELL TRANSPLANT INTRODUCTION This booklet was designed to help you and the important people in your life understand the treatment of high dose chemotherapy with stem cell support: a procedure
More informationPATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr CYRAMZA ramucirumab Read this carefully before you receive CYRAMZA (pronounced "si ram - ze"). This leaflet is a
More informationJeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins)
Jeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins) I HEAR YA KNOCKING BUT YOU CAN T COME IN (electrolytes) TAKE MY BREATH AWAY (Opiates-morphine) OUT WITH
More informationCytotoxic and Biotherapies Credentialing Programme Module 2
Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal
More informationAdjuvant Chemotherapy 1. Vinorelbine-25/Cisplatin-80 (chemo alone) CTIS 1722 4 2. Gemcitabine-1250/Carboplatin-5AUC CTIS 1601 5
LUNG CANCER Section by: Dr Conrad Lewanski, Dr Danielle Power, Dr Tom Newsom-Davis Version; Lung Cancer Regimens v4.3 NWLCN 20Feb12 Section last reviewed: 1 st July 2011 Section last corrected: 20 th February
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012
Background LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 The incidence of pancreatic cancer in the UK is 9.4/100,000. It is
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress Rescue Chemotherapy Protocols for Dogs with Lymphoma Kenneth M. Rassnick, DVM, DACVIM (Oncology) Cornell University
More informationPOAC CLINICAL GUIDELINE
POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal
More information